➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Merck
Moodys
Mallinckrodt
Baxter

Last Updated: October 29, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,778,394

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,778,394 protect, and when does it expire?

Patent 8,778,394 protects DSUVIA and is included in one NDA.

This patent has seventy patent family members in twelve countries.

Summary for Patent: 8,778,394
Title:Small-volume oral transmucosal dosage forms
Abstract: Small-volume oral transmucosal dosage forms or NanoTabs.RTM. comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs.RTM. to administer a drug for the treatment of acute, post-operative or breakthrough pain.
Inventor(s): Palmer; Pamela (San Francisco, CA), Schreck; Thomas (Portola Valley, CA), Tzannis; Stelios (Petaluma, CA), Hamel; Larry (Pacific Grove, CA), Poutiatine; Andrew I. (Mill Valley, CA)
Assignee: AcelRx Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:13/561,543
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Delivery; Device; Dosage form;

Drugs Protected by US Patent 8,778,394

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF ACUTE PAIN   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,778,394

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 474564   Start Trial
Canada 2636088   Start Trial
Canada 2636115   Start Trial
Canada 2636119   Start Trial
Canada 2673837   Start Trial
Canada 2673856   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Moodys
McKinsey
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.